DV
Dividend Vision

MLYS — Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. (MLYS)

Total return is 60.2% over the past 3.5 years, 39.2 points behind SPY at 99.4%. Its deepest 1-year drawdown was 52.5%.

This appears to be a single stock listing rather than an ETF, representing Mineralys Therapeutics, Inc., a biopharmaceutical equity security. The holding does not currently distribute dividends and carries no stated expense ratio as a direct stock position. This security would appeal primarily to growth-oriented investors seeking exposure to the therapeutic development sector rather than income-focused investors.

MLYS key facts

Asset type
Stock
Asset class
Equity
Inception date
02/09/2023
Distribution frequency
None
Last close
$25.64
Market cap
$2,266,752,512
Average volume
697700.0
Beta
0.681
Payout ratio
0.0
Forward P/E
0.0
EPS
$-4.20